- Home
- ATHA vs NCEL Comparison
ATHA vs NCEL Comparison
Compare ATHA & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATHA | NCEL |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Switzerland |
| Employees | 26 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 20.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATHA | NCEL |
|---|---|---|
| Price | $6.91 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 123.7K |
| Earning Date | 02-26-2026 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $1.89 |
| 52 Week High | $8.36 | $7.64 |
Technical Indicators
Market Signals| Indicator | ATHA | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | N/A |
| Support Level | $6.41 | N/A |
| Resistance Level | $7.64 | N/A |
| Average True Range (ATR) | 0.69 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 68.86 | 0.00 |
Price Performance
Historical ComparisonAbout ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.